JCM Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Raboud, J. M.
Right arrow Articles by Montaner, J. S. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Raboud, J. M.
Right arrow Articles by Montaner, J. S. G.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, November 1998, p. 3369-3371, Vol. 36, No. 11
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Comparison of Costs of Strategies for Measuring Levels of Human Immunodeficiency Virus Type 1 RNA in Plasma by Using Amplicor and Ultra Direct Assays

J. M. Raboud,1,2,* E. Seminari,3 S. L. Rae,1 P. R. Harrigan,4 R. S. Hogg,2,4 B. Conway,4 C. Sherlock,4 M. T. Schechter,1,2,4 M. V. O'Shaughnessy,1,4,5 and J. S. G. Montaner1,4,6

Canadian HIV Trials Network,1 B.C. Centre for Excellence in HIV/AIDS,4 and Department of Health Care and Epidemiology,2 Department of Medicine,6 and Department of Pathology and Laboratory Medicine,5 University of British Columbia, Vancouver, British Columbia, Canada, and Istituto di Clinica di Macattie Infettive, Policlinico S. Matteo, Pavia, Italy3

Received 6 March 1998/Returned for modification 11 May 1998/Accepted 18 August 1998

The costs of four algorithms for monitoring plasma human immunodeficiency virus type 1 RNA were compared. For patients with strong virologic responses, the use of Ultra Direct exclusively was the cheapest strategy. For patients with weak virologic responses, small savings could be obtained by using Amplicor and retesting only samples with values below 500 copies/ml with Ultra Direct.

* Corresponding author. Mailing address: Canadian HIV Trials Network, St. Paul's Hospital, 620-1081 Burrard St., Vancouver, B.C. V6Z 1Y6, Canada. Phone: (604) 631-5443. Fax: (604) 631-5005. E-mail: jraboud{at}hivnet.ubc.ca.

Journal of Clinical Microbiology, November 1998, p. 3369-3371, Vol. 36, No. 11
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 1998 by the American Society for Microbiology. All rights reserved.